Filgotinib (BioDeep_00000179050)
human metabolite blood metabolite
代谢物信息卡片
化学式: C21H23N5O3S (425.15215280000007)
中文名称: N-[5-[4-[(1,1-二氧代-4-硫代吗啉基)甲基]苯基][1,2,4]三唑并[1,5-A]吡啶-2-基]环丙烷甲酰胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
InChI: InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
描述信息
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- PubChem: 49831257
- HMDB: HMDB0252256
- DrugBank: DB14845
- ChEMBL: CHEMBL3301607
- Wikipedia: Filgotinib
- chemspider: 28189566
- CAS: 1206161-97-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Florence Namour, Kacey Anderson, Cara Nelson, Chantal Tasset. Filgotinib: A Clinical Pharmacology Review.
Clinical pharmacokinetics.
2022 06; 61(6):819-832. doi:
10.1007/s40262-022-01129-y. [PMID: 35637376] - Kacey Anderson, Cara H Nelson, Qi Gong, Muhsen Alani, Thomas Tarnowski, Ahmed A Othman. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
Clinical pharmacology in drug development.
2022 02; 11(2):235-245. doi:
10.1002/cpdd.1015. [PMID: 34468080] - Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng, Julie A Di Paolo. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Annals of the rheumatic diseases.
2021 07; 80(7):865-875. doi:
10.1136/annrheumdis-2020-219012. [PMID: 33741556] - Matthew Baker, Yashaar Chaichian, Mark Genovese, Vimal Derebail, Panduranga Rao, Winn Chatham, Michael Bubb, Sam Lim, Hooman Hajian, Oksana Gurtovaya, Uptal Patel, James Tumlin. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.
RMD open.
2020 12; 6(3):. doi:
10.1136/rmdopen-2020-001490. [PMID: 33380521] - Haitham AlRabiah, Adnan A Kadi, Mohamed W Attwa, Gamal A E Mostafa. Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 Oct; 1154(?):122195. doi:
10.1016/j.jchromb.2020.122195. [PMID: 32943176] - Ashok Zakkula, Shobha Pulipati, Sreekanth Dittakavi, Ram Murthi Bestha, Mohd Zainuddin, Ravi Kumar Trivedi, Ramesh Mullangi. Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study.
Drug research.
2020 May; 70(5):233-238. doi:
10.1055/a-1141-3475. [PMID: 32289835] - Abhishek Dixit, Vinay Kiran, Bhavesh Babulal Gabani, Zainuddin Mohd, Ravi Kumar Trivedi, Ramesh Mullangi. Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats.
Biomedical chromatography : BMC.
2020 Apr; 34(4):e4802. doi:
10.1002/bmc.4802. [PMID: 31998982] - Kacey Anderson, Yan Xin, Hao Zheng, Chohee Yun, Ellen Kwan, Ann Qin, Florence Namour, Brian P Kearney, Anita Mathias. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
Clinical pharmacology in drug development.
2020 01; 9(1):32-40. doi:
10.1002/cpdd.755. [PMID: 31797578] - Martin E Dowty, Tsung H Lin, Michael I Jesson, Martin Hegen, David A Martin, Vaibhav Katkade, Sujatha Menon, Jean-Baptiste Telliez. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Pharmacology research & perspectives.
2019 12; 7(6):e00537. doi:
10.1002/prp2.537. [PMID: 31832202] - Kacey Anderson, Hao Zheng, Mona Kotecha, Jennifer Cuvin, Bob Scott, Shringi Sharma, Ann Ran-Ran Qin, Florence Namour, Yan Xin. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Clinical pharmacology in drug development.
2019 07; 8(5):585-594. doi:
10.1002/cpdd.659. [PMID: 30768860] - Florence Namour, Liesbeth Fagard, Annegret Van der Aa, Pille Harrison, Yan Xin, Chantal Tasset. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
British journal of clinical pharmacology.
2018 12; 84(12):2779-2789. doi:
10.1111/bcp.13726. [PMID: 30088677] - Frédéric Vanhoutte, Minodora Mazur, Oleksandr Voloshyn, Mykola Stanislavchuk, Annegret Van der Aa, Florence Namour, René Galien, Luc Meuleners, Gerben van 't Klooster. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Arthritis & rheumatology (Hoboken, N.J.).
2017 10; 69(10):1949-1959. doi:
10.1002/art.40186. [PMID: 28622463]